Fraudulent Zika Claims Are CDER's Latest Extermination Target

CDER is on the lookout for companies seeking to capitalize off the Zika health crisis with fraudulent claims about their products’ ability to treat or prevent the disease, says Brad Price, acting director of the Division of Nonprescription Drugs and Health Fraud, Office of Compliance.

More from Archive

More from HBW Insight